FDA inspection
Pfizer Pharmaceuticals LLC: FDA inspection ending Jan 11, 2008
FDA inspection 502437 · Voluntary Action Indicated (VAI) · Vega Baja, PR
Key facts
| Inspection ID | 502437 |
|---|---|
| Firm | Pfizer Pharmaceuticals LLC |
| FEI number | 2623619 |
| Address | Road 689, Km 1.9 |
| City | Vega Baja |
| State | PR |
| ZIP | 00693 |
| Fiscal year | 2008 |
| Inspection end date | Jan 11, 2008 |
| Classification | Voluntary Action Indicated (VAI) |
| Project area | Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|New Drug Evaluation|Unapproved and Misbranded Drugs|New Drug Evaluation|Unapproved and Misbranded Drugs|New Drug Evaluation|Unapproved and Misbranded Drugs|New Drug Evaluation|Unapproved and Misbranded Drugs|New Drug Evaluation|Unapproved and Misbranded Drugs|New Drug Evaluation|Unapproved and Misbranded Drugs|New Drug Evaluation|Unapproved and Misbranded Drugs|New Drug Evaluation|Unapproved and Misbranded Drugs|New Drug Evaluation|Unapproved and Misbranded Drugs|New Drug Evaluation|Unapproved and Misbranded Drugs|New Drug Evaluation|Unapproved and Misbranded Drugs|New Drug Evaluation|Unapproved and Misbranded Drugs|New Drug Evaluation|Unapproved and Misbranded Drugs|New Drug Evaluation|Unapproved and Misbranded Drugs|New Drug Evaluation|Unapproved and Misbranded Drugs|New Drug Evaluation|Unapproved and Misbranded Drugs|New Drug Evaluation|Unapproved and Misbranded Drugs|New Drug Evaluation|Unapproved and Misbranded Drugs|New Drug Evaluation|Unapproved and Misbranded Drugs|New Drug Evaluation|Unapproved and Misbranded Drugs|New Drug Evaluation|Unapproved and Misbranded Drugs|New Drug Evaluation|Unapproved and Misbranded Drugs|New Drug Evaluation|Unapproved and Misbranded Drugs|New Drug Evaluation|Unapproved and Misbranded Drugs|New Drug Evaluation|Unapproved and Misbranded Drugs|New Drug Evaluation|Unapproved and Misbranded Drugs|New Drug Evaluation|Unapproved and Misbranded Drugs|New Drug Evaluation|Unapproved and Misbranded Drugs|New Drug Evaluation|Unapproved and Misbranded Drugs|New Drug Evaluation|Unapproved and Misbranded Drugs|New Drug Evaluation|Unapproved and Misbranded Drugs|New Drug Evaluation|Unapproved and Misbranded Drugs|New Drug Evaluation|Unapproved and Misbranded Drugs|New Drug Evaluation|Unapproved and Misbranded Drugs|New Drug Evaluation|Unapproved and Misbranded Drugs|New Drug Evaluation|Unapproved and Misbranded Drugs|New Drug Evaluation|Unapproved and Misbranded Drugs|New Drug Evaluation|Unapproved and Misbranded Drugs|New Drug Evaluation|Unapproved and Misbranded Drugs|New Drug Evaluation|Unapproved and Misbranded Drugs|New Drug Evaluation|Unapproved and Misbranded Drugs|New Drug Evaluation|Unapproved and Misbranded Drugs|New Drug Evaluation|Unapproved and Misbranded Drugs|New Drug Evaluation|Unapproved and Misbranded Drugs|New Drug Evaluation|Unapproved and Misbranded Drugs|New Drug Evaluation|Unapproved and Misbranded Drugs|New Drug Evaluation|Unapproved and Misbranded Drugs|New Drug Evaluation|Unapproved and Misbranded Drugs|New Drug Evaluation|Unapproved and Misbranded Drugs|New Drug Evaluation|Unapproved and Misbranded Drugs|New Drug Evaluation|Unapproved and Misbranded Drugs|New Drug Evaluation|Unapproved and Misbranded Drugs|New Drug Evaluation|Unapproved and Misbranded Drugs|New Drug Evaluation|Unapproved and Misbranded Drugs|New Drug Evaluation|Unapproved and Misbranded Drugs|New Drug Evaluation|Unapproved and Misbranded Drugs|New Drug Evaluation|Unapproved and Misbranded Drugs|New Drug Evaluation|Unapproved and Misbranded Drugs|New Drug Evaluation|Unapproved and Misbranded Drugs|New Drug Evaluation|Unapproved and Misbranded Drugs|New Drug Evaluation|Unapproved and Misbranded Drugs|New Drug Evaluation|Unapproved and Misbranded Drugs|New Drug Evaluation|Unapproved and Misbranded Drugs|New Drug Evaluation|Unapproved and Misbranded Drugs|New Drug Evaluation|Unapproved and Misbranded Drugs|New Drug Evaluation|Unapproved and Misbranded Drugs|New Drug Evaluation|Unapproved and Misbranded Drugs|New Drug Evaluation|Unapproved and Misbranded Drugs|New Drug Evaluation|Unapproved and Misbranded Drugs|New Drug Evaluation|Unapproved and Misbranded Drugs|New Drug Evaluation|Unapproved and Misbranded Drugs |
| Product type | Drugs |
At a glance
- None Citations
- 1–9 Posted citations
- No Warning letter followed
- Yes Form FDA 483 issued
- No Establishment inspection report (EIR) exists
- 10–99 Inspections at this FEI
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA inspections
FDA inspections are classified as No Action Indicated (NAI), Voluntary Action Indicated (VAI) or Official Action Indicated (OAI). Inspections of individual clinical investigators are not published here.
Source: U.S. Food and Drug Administration (FDA), inspection classification data